[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infectious-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infectious-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,68,120,144,172,197,225,256,284,308],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":4,"leadSponsor":40,"locationsCount":43},"100054343","studies-of-the-pathogenesis-of-hiv-infection-in-human-peripheral-blood-cells-andor-body-fluids-in-people-living-with-and-without-hiv-100054343",false,"NCT00001281","Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and\u002For Body Fluids in People Living With and Without HIV","* INCLUSION CRITERIA:\n* 18 years of age or older.\n* Adequate venous access.\n* Have a blood pressure less than or equal to 180\u002F100: pulse rate 50-100, unless a lower pulse rate is considered normal for the volunteer.\n* Have adequate blood counts (volunteers living with HIV: hemoglobin greater than or equal to 9.0 g\u002FdL, platelets greater than or equal to 50,000; volunteers living without HIV: hemoglobin greater than or equal to 9.0 g\u002FdL, platelets greater than or equal to 50,000\n* Be willing and able to provide written informed consent on screening, comply with study requirements and procedures, and comply with clinic policies\n* Willingness to allow blood samples to be used for future studies of HIV infection\u002Fpathogenesis, and undergo hepatitis screening\n\nEXCLUSION CRITERIA:\n\n* Pregnant and\u002For breastfeeding females.\n* Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise volunteer safety.",true,"ALL","18 Years","120 Years",{"count":20,"type":21},2419,"ESTIMATED","OBSERVATIONAL","We are studying virologic and\u002For immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-infectious immune regulation and dysregulation using human peripheral blood mononuclear cells as a model.",[25,26,27],"HIV","Immunodeficiencies","Infectious Diseases",[29,30,31,32],"Lymphocytes","Venipuncture","Mononuclear Cells","Natural History","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"1993-03-09",{"name":41,"class":42},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100643096","research-project-on-the-interaction-between-immune-function-and-infectious-diseases-in-older-adults-and-the-development-of-prevention-and-control-strategies-100643096","NCT07644962","Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies","Inclusion Criteria:\n\n\\- General Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.\n2. Male or female.\n3. Able to understand the study and voluntarily provide written informed consent.\n\nInfection Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older, regardless of sex.\n2. Patients with an infectious disease diagnosed by a qualified clinician.\n\nExclusion Criteria:\n\n* General Cohort Exclusion Criteria\n\n  1. Refusal to participate in this study.\n  2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nInfection Cohort Exclusion Criteria\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).\n2. Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.\n3. Refusal to participate in this study.\n4. Critically ill patients or those unable to cooperate with specimen collection procedures.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.","60 Years",{"count":52,"type":21},23000,"As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.\n\nBuilding upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.",[27,55,56],"Immunosenescence","Aging","NOT_YET_RECRUITING","2026-06-08",{"date":60,"type":37},"2026-06-12",{"date":62,"type":21},"2026-06-09",{"date":64,"type":21},"2029-12-30",{"name":66,"class":67},"Huashan Hospital","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":101,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","FEMALE","12 Years",{"count":79,"type":21},1040,"INTERVENTIONAL",[82],"NA","The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[85,86,87,88,89,90,27,91,92,93,94,95,96,97,98,99,100],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Anemia","Child Development","Weight Loss","Blood Pressure","Mental Health","Diarrhea","Coughing","Eczema","Allergies","Antibiotic Use",[102,103,104,105,106,107,108,109],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","2026-04-28",{"date":112,"type":37},"2026-05-06",{"date":114,"type":21},"2026-06-01",{"date":116,"type":21},"2028-02-28",{"name":118,"class":67},"Swiss Tropical & Public Health Institute",1,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100582536","a-study-to-learn-about-the-study-medicine---zavicefta-in-patients-with-sepsis-or-loss-of-kidney-function-in-japan-100582536","NCT06864585","A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan","Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL\u002FMin) -","Inclusion Criteria:\n\n1. Patients who received Zavicefta for the first time after the launch of Zavicefta\n2. Patients who received Zavicefta for an infectious diseases indicated for Zavicefta\n3. Patients with diagnosis of sepsis and\u002For renal impairment (creatinine clearance ≤ 50mL\u002Fmin) at the start of the treatment with Zavicefta\n4. Individuals who understand the nature of this study and give consent for the provision of the information collected in this study to third parties and the use of the information for other than intended use\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this study.","0 Years",{"count":129,"type":21},59,"The purpose of this study is to learn about the safety and how effective is Zavicefta under actual clinical practice in Japan.\n\nZavicefta is a combination of Avibactam sodium and Ceftazidime hydrate.\n\nThis study is seeking for patients with:\n\n* sepsis (A very serious infection in your blood caused by germ (a bacteria)) or\n* renal impairment (loss of kidney function) who are administrated with Zavicefta for the first time.\n\nSubjects will take part in this study from the start date of receiving Zavicefta (Day 1) to Day 28.",[27],[133],"Sepsis; Renal impairment; Zavicefta; Avibactam; Ceftazidime","2026-04-17",{"date":136,"type":37},"2026-04-20",{"date":138,"type":21},"2026-09-15",{"date":140,"type":21},"2029-03-30",{"name":142,"class":143},"Pfizer","INDUSTRY",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":80,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":119},"100619622","prescription-support-system-for-antimicrobial-use-in-belgian-primary-care-100619622","NCT07347015","Prescription Support System for Antimicrobial Use in Belgian Primary Care","Impact Evaluation of a Prescription Search Support (PSS) for Antimicrobials Using a Stepped-Wedge Cluster Randomized Design in Belgian Primary Care","PaSSo","Inclusion Criteria:\n\n* General practices in Belgium using compatible EHR systems.\n* Willingness to use and activate the PSS by giving consent.\n* Agreement to participate in the study, provided signed informed consent form is in place.\n\nExclusion Criteria:\n\n* Practices using an EHR system that solely allows a single sign-on to the standalone PSS.\n* Practices already using a similar PSS or participating in overlapping projects.",{"count":153,"type":21},48,[82],"Inappropriate antibiotic prescribing in primary care remains an important contributor to antimicrobial resistance. Despite the availability of evidence-based clinical guidelines, antibiotics are still frequently prescribed for self-limiting infections. Digital clinical decision support tools may help general practitioners (GPs) align prescribing decisions with guideline recommendations during patient consultations.\n\nThis study evaluates the impact of a digital Prescription Support System (PSS) designed to support antimicrobial prescribing in Belgian primary care. The PSS provides guideline-based recommendations derived from the Belgian BAPCOC guidelines for common infections in ambulatory care. Recommendations are presented through a user-friendly decision tree that is integrated into existing electronic health record systems and can be consulted during routine care.\n\nThe study is embedded within the national implementation strategy of the PSS coordinated by the National Institute for Health and Disability Insurance (RIZIV-INAMI). A stepped-wedge cluster randomized design is used, in which participating general practices transition sequentially from usual care to access to the PSS over four predefined implementation steps. This approach ensures that all participating practices eventually receive access to the system while allowing comparisons over time.\n\nThe primary objective is to assess whether implementation of the PSS is associated with changes in antibiotic prescribing in Belgian general practice. Prescribing outcomes are measured using routinely collected indicators from the Belgian Antibiotic Barometer, including overall antibiotic prescribing rates and the use of broad- versus narrow-spectrum antibiotics. Secondary objectives include assessing the usability and acceptability of the PSS among clinicians and identifying factors that influence its adoption in daily practice. The study will also monitor potential unintended consequences, such as changes in workflow or concerns about underprescribing.\n\nFindings from this study will inform future decisions regarding further optimization and wider implementation of the PSS in Belgian primary care.",[27],[158,159,160,161,162],"Antimicrobial Stewardship","Primary Care","Clinical Decision Support","Stepped-Wedge Cluster Randomized Trial","Antibiotics","2026-03-05",{"date":165,"type":37},"2026-03-06",{"date":167,"type":37},"2025-12-21",{"date":169,"type":21},"2027-03-31",{"name":171,"class":67},"KU Leuven",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":80,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":119},"100624199","fostering-prosocial-preventive-behaviours-through-awe-100624199","NCT07406529","Fostering Prosocial Preventive Behaviours Through Awe","Fostering Prosocial Behaviours Against Infectious Diseases Through Awe: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults (age ≥18 years) who live in\n* Hong Kong, Singapore, and ten major cities in Mainland China (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chongqing, Chengdu, Wuhan, Xi'an, Nanjing) over the past one year\n* Able to read and understand written Chinese or English\n* Have access to the internet through computers, mobile phones, or tablets\n\nExclusion Criteria:\n\n* Individuals with cognitive or linguistic difficulties that would prevent them from completing an online survey will be excluded.",{"count":180,"type":21},456,[82],"The goal of this randomized control trial is to investigate the impact pf awe on prosocial preventive behaviours against infectious diseases among adults from Hong Kong, Singapore, and ten major cities in Mainland China (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chongqing, Chengdu, Wuhan, Xi'an, Nanjing). The main questions it aims to answer are:\n\n* Does experiencing awe increase adults' intentions to engage in prosocial preventive behaviours against infectious diseases, including vaccination, mask wearing, and social distancing?\n* Does the impact vary across three research sites?",[27],[185,186,187],"preventive behaviour","infectious diseases","awe","2026-02-24",{"date":190,"type":37},"2026-02-27",{"date":192,"type":37},"2025-10-27",{"date":194,"type":21},"2026-10-31",{"name":196,"class":67},"The University of Hong Kong",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":80,"phases":206,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":119},"100595244","phase-1-a-phase-1-study-of-the-safety-and-tolerability-of-single-and-multiple-ascending-doses-of-bwc0977-in-healthy-volunteers-100595244","NCT07029932","A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers","A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Age: Healthy male or female 18 to 55 years of age, inclusive, at time of consent\n2. Body mass index (BMI): BMI ≥ 19.0 and ≤ 30.0 (kg\u002Fm2) and weight between 55.0 and 100.0 kg (inclusive)\n3. Health Status: Medically healthy without significant history of any chronic diseases or conditions (such as cardiovascular, renal, hepatic, neurological, hematological, gastrointestinal, endocrine, or musculoskeletal disorders). Volunteers must have no clinically significant abnormalities in medical history, as determined by the Investigator.\n4. Screening Tests:\n\n   1. No findings in Physical examination or vital signs (including temperature, heart rate, respiratory rate, and blood pressure) that the Investigator determines would interfere with interpretation of study results\n   2. Triplicate ECGs without clinically significant abnormalities, including a QTcF interval duration ≤450 msec (for males), and ≤470 msec (for females), obtained as an average from the triplicate screening ECGs after at least 5 minutes in a supine, quiet-rest position\n   3. For clinically significant abnormalities in the screening clinical laboratory tests, vital signs, and ECG assessments as determined by the Investigator, repeat testing could be performed at the Investigator's discretion\n5. Informed consent: Willing and able to provide written informed consent\n6. Compliance: Agrees to be available for all study visits and cooperate fully with the requirements of the study protocol, including the schedule of events.\n7. Physical Activity Restrictions: Willing to refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from 4 days prior to admission in the clinical research unit (CRU) until completion of the study.\n8. Venous Access: Have suitable venous access for drug administration and blood sampling\n9. Contraception Requirements (for those of reproductive potential): Contraception requirements will follow institutional policies.\n\n   Females:\n\n   Must agree to use two forms of effective contraception-male partner using a condom plus 1 other highly effective method of birth control (e.g., Hormonal methods of contraception including oral contraceptives {includes Combined estrogen-progestin oral contraceptives (COCs) and progestogen-only contraceptives associated with inhibition of ovulation}, a vaginal ring, injectable and implantable hormonal contraceptives, indwelling intrauterine device, history of bilateral tubal ligation, sole vasectomized (bilateral vasectomy) partner with documented azoospermia 90 days after procedure) from signing the consent form until 33 days after last study drug administration, or agree to complete sexual abstinence for the duration of the study from screening and for 33 days after last study drug administration. Females of child-bearing potential must also agree not to donate ova or oocytes (i.e., human eggs) during the study, and for 33 days after completion of the study. For female participants, hormonal contraceptives should begin at least 1 month prior to screening to ensure the contraceptive is in full effect.\n\n   To be considered of non-childbearing potential, a female must have either a hysterectomy, bilateral salpingo-oophorectomy (at least 3 months prior to screening), or menopause {last menstruation \\>12 months in the absence of other biological causes and follicle-stimulating hormone levels in menopausal range (\\>40mIU\u002FmL)}, provision of written documentation is not required for female sterilization and oral confirmation is adequate. Female participants in same sex relationships do not need to utilize contraception.\n\n   Males:\n\n   If sexually active with a female partner of childbearing potential, must agree to use male condom plus 1 other highly effective method of birth control in their partner (e.g., Hormonal methods of contraception including oral contraceptives {includes Combined estrogen-progestin oral contraceptives (COCs) and progestogen-only contraceptives associated with inhibition of ovulation}, a vaginal ring, injectable and implantable hormonal contraceptives, indwelling intrauterine device, history of bilateral tubal ligation) from signing the consent form until 93 days after last study drug administration, or agree to complete sexual abstinence for the duration of the study from screening and for 93 days after last study drug administration. Hormonal contraceptives should be in use by female partner for at least 1 month prior to screening to ensure contraceptive is in full effect.\n\n   To be considered surgically sterile, male participants must have had bilateral vasectomy at least 3 months before screening with appropriate documentation of the absence of sperm in the ejaculate 90 days after procedure. The use of condom by male partner will be required if bilateral vasectomy is the chosen highly effective method of birth control.\n\n   Male participants must also agree not to donate sperms during the study and for 93 days after the last dose of the study drug.\n\n   Male participants in same sex relationships or sexually active with female of non-childbearing potential (as defined above) do not need to utilize contraception. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level\n\n   Exclusion Criteria:\n   * 1\\) Pregnancy and Lactation: Women who are pregnant and\u002For lactating. 2) Significant Medical History: History or presence of significant cardiovascular (including QT prolongation, clinically significant hypokalemia, or other proarrhythmic conditions), pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine (including glucose intolerance, diabetes mellitus), immunologic (including asthma or seasonal allergies \\[that require intermittent use of steroids or other medication\\]), musculoskeletal (including tendinopathy), dermatologic, or neurological disease (including seizure disorders, psychiatric disorders), including any acute illness or surgery within the past 3 months, as determined by the Investigator to be clinically relevant.\n\n     1. History of any kidney disease or current or chronic history of impaired renal function as indicated by a calculated creatinine clearance (Cockcroft-Gault formula) \\\u003C80 milliliter per minute (mL\u002Fmin).\n     2. Current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert syndrome or asymptomatic gallstones) 3) Laboratory abnormalities\n\n     a) Clinically significant abnormal findings in serum chemistry, hematology, coagulation or urinalysis results obtained at screening or check-in (Day-1) b) Alanine aminotransferase (ALT) more than (\\>)1 upper limit of normal (ULN) at screening or check-in (Day-1) c) Aspartate aminotransferase (AST) \\> ULN at screening or check-in (Day-1)d) Bilirubin \\>ULN at screening or check-in (Day-1) e) Serum creatinine \\> ULN at screening or check-in (Day-1). The serum creatinine or any laboratory test may be repeated prior to confirming exclusion, at the PI's discretion.\n\n     4\\) Electrocardiographic abnormalities: Baseline QTcF of \\>450 msec (for males), and \\>470 msec (for females) at screening or check-in (Day-1) 5) Photosensitivity: History of photosensitivity to quinolones 6) Clostridium Difficile: History of known or suspected Clostridium difficile infection 7) Hospitalization History: Any condition that necessitated hospitalization within the 3 months prior to Day -1 or is likely to require so during the study 8) Antibiotic History: No systemic antibiotic use within 5 days before dosing. 9) Infection History: Positive test for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV antibodies), or human immunodeficiency virus antibody (antibodies to HIV-1, HIV-2) at screening.\n\n     10\\) Recent Medications: Exclude participants receiving all prescription and OTC medications (except hormonal contraception and Paracetamol) 14 days or 5 half-lives, whichever is longer, prior to IP dosing.Discussion between the PI and the Sponsor Medical Monitor is encouraged regarding prior use of any medications during the pre-dose period. Note: An exception is made for hormonal contraceptives, paracetamol (a maximum of 4 doses per day of 500 mg, and no more than 3 g per week) for the treatment of headache or any other pain as per the PI's judgement.\n\n     11\\) Hypersensitivity: DocumentedHistory of significant hypersensitivity reaction or anaphylaxis to any medication, as determined by the Medical Officer.\n\n     12\\) Tobacco and Nicotine Use: Smoker (including tobacco, e-cigarettes, or marijuana) or nicotine user within 1 month prior to dosing and have a positive test for cotinine at check in on Day -1 (may be repeated once, at the discretion of the Investigator or Medical officer, in the instance of a positive result).\n\n     13\\) Drug\u002FAlcohol Abuse: Positive urine drug\u002Falcohol breath testing at screening or check-in (Day -1), or history of substance abuse or alcohol abuse (defined as greater than 2 standard drinks on average each and every day, where one standard drink is defined as containing 10 g of alcohol and is equivalent to 1 can or stubby of mid-strength beer, 30 ml nip spirits, or 100 ml wine) within the previous 5 years (may be repeated once per timepoint, at the discretion of the Investigator or Medical officer, in the instance of a positive result).\n\n     14\\) Blood\u002FPlasma Donation: Donation of blood within 30 days or plasma within 7 days prior to randomization, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of study enrollment.\n\n     15\\) Previous Study Participation: Previous participation in this study, i.e., who has already completed earlier cohorts or previous participation in another study within 5 half-lives (if known) of the agent, or 30 days, whichever is longer, of Day 1.\n\n   Note: prior participation at any time in non-invasive methodology trials in which no drugs were given is acceptable. Those who were screen failures or not dosed in this study may will be considered for re-screening in subsequent cohorts.\n\n16\\) Food Restrictions: Consumption of red wine, Seville oranges, grapefruit, or grapefruit juice, pummelos, exotic citrus fruits, grapefruit hybrids, or fruit juices containing such products from 7 days prior to the first dose of study medication.(Note: Lemon and lime, including their juice or zest, are permitted as they are not known to significantly affect cytochrome P450 (CYP3A4) enzyme activity) 17) Sponsor Relationships: Employee or family member of an employee of the Sponsor, CRU, or clinical research organization at which the study will be conducted.\n\n18\\) Non-compliance: Unable to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be non-compliant with any study requirements.\n\n19\\) Other Medical Conditions: Any other disease or condition that, in the opinion of the Investigator, would preclude the subject's participation in the study or place them at risk as a result of study participation.\n\nNote: Volunteers should refrain from consumption of any foods containing poppy seeds within 48 hours (2 days) prior to screening and prior to Day -1 to avoid false positive drug screen results. Examples of foods to avoid include: poppy seed bagels, muffins, pastries, salad dressings, or any baked goods or dishes that list poppy seeds as an ingredient.","55 Years",{"count":153,"type":21},[207],"PHASE1","The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of BWC0977 when administered to healthy adult volunteers.",[27,210],"Antimicrobial Drug Resistance",[212,213,214,215],"safety","Tolerability","Pharmacokinetics","BWC0977","2025-11-19",{"date":218,"type":37},"2025-11-24",{"date":220,"type":37},"2025-10-10",{"date":222,"type":21},"2026-08-30",{"name":224,"class":143},"Bugworks Research Inc.",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":234,"studyType":22,"phases":4,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":255},"100574647","impaired-type-i-ifn-immunity-due-to-autoantibodies-or-a-genetic-defect-a-prospective-national-cohort-100574647","NCT06762002","Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort","COVIFERON","Inclusion Criteria:\n\n* Age \\>18 years\n* History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI)\n* Affiliated to social security\n* Written informed consent\n\nExclusion Criteria:\n\n* Participation to an interventional clinical trial on a pharmacological treatment\n* Clinical condition leading to life expectancy less than 1 year\n* Subject to a legal protection measure (safeguard of justice, curatorship, tutorship)\n* Individuals deprived of freedom",{"count":233,"type":21},500,"3 Years","The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections. In the context of the COVID-19 pandemic, the following results have identified 1) several inborn errors of immunity (IEI) affecting the response or production of type I interferons (type I IFNs) in around 4% of adult patients with severe clinical disease, and 2) the presence of type I IFN-neutralizing autoantibodies (auto-Abs) in around 15% of severe cases, and 20% of deaths. The investigators would like to carry out a longitudinal immunological and clinical follow-up study on a prospective cohort of patients with either a genetic defect affecting the type I IFN-dependent immune response, or anti-IFN-I auto-Abs, to monitor the incidence of infectious and\u002For autoimmune events in these individuals, the evolution of neutralizing power, and the kinetics of auto-Abs. This should lead to a better understanding of the prevention and management of these patients.\n\nThe research design is a national multicenter prospective cohort of adults with 1) anti-IFN-I auto-Abs or 2) IEI- IFN-I, with follow-up from 1 to 4 years. These individuals may be: 1) patients who have or have had clinical disease (related to COVID-19, other viral infections, autoimmune disorders); or 2) \"healthy\" participants (e.g. blood donors, relatives of an IEI patient).\n\nFollow-up will include:\n\n* yearly visits to the Clinical Investigation Center (CIC) or a clinical department with blood sampling;\n* specific visit in case of hospitalization for infectious events or adverse effects of vaccination, exacerbation or new diagnosis of auto-immune disease, new diagnosis of cancer, or SARS-CoV-2 infection whether or not patients are admitted to hospital, with blood sampling.\n\nIn addition, a retrospective \"passive\" follow-up will be implemented through matching with the data from the SNDS (National Health Data System), in order to collect clinical events of and healthcare resource consumption. Moreover, matching with controls adults from the national CONSTANCES cohort, not carrying auto-Abs against type I IFNs nor IEI-IFN-I, will be performed. (ratio 3:1; matching on age (+\u002F- 5 years), gender and geographic region of recruitment). Individuals under long-lasting immunosuppressive or immunomodulatory drugs will not be eligible. Follow-up of controls, which will be carried out as part of the CONSTANCES cohort, will include web-based questionnaires, every 12 months, in addition to linking with SNDS data as already done in this cohort.\n\nInclusion visit:\n\nAfter signing the consent form, the following tests will be performed:\n\n* Demographic characteristics (sex, age, country of birth)\n* Medical history from participant and family member(s) including infectious and auto-immune diseases, cancers and vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigations (anti-nuclear, anti-ENA, native anti-DNA, anti- thyroid antibodies, rheumatoid factor);\n  * immunophenotyping\\*;\n  * auto-Abs against type I IFNs, other cytokines\\*, or other target proteins\\* (dosage and neutralization activity);\n  * Genetic explorations by whole-exome or whole-genome sequencing\\*;\n  * Biobanking (DNA, plasma\u002Fsera; cryopreserved peripheral blood mononuclear cells (PBMCs).\n\n    * these biological analyses will be carried out as part of dedicated COVIFERON RHU5 workpackages.\n\nIn addition, vaccination against SARS-CoV-2 and influenza will be offered to these subjects as a priority, as part of their usual care.\n\nFollow-up visits :\n\nAnnual visits to the CIC :\n\n* Medical history since last visit, including infectious, auto-immune and oncologic events, vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigation (anti-nuclear, anti-ENA, native anti- DNA, anti-thyroid antibodies, rheumatoid factor);\n  * immunophenotyping;\n  * Auto-Abs against type I IFNs, other cytokines, or other target proteins (dosage and neutralization)\n  * Biobanking (DNA, plasma, cryopreserved peripheral blood mononuclear cells (PBMCs))\n\nAdditional specific visit in the event of a clinical event of interest, at any time during follow-up:\n\n* In case of SARS-CoV-2 infection, whatever the severity of the disease: blood sampling for determination and neutralization of type I anti-IFN autoAbs, CBC, and biobanking (plasma and PBMC) and teleconsultation with the CIC in charge of patients, as soon as possible.\n* In the event of hospitalization for infectious events or exacerbation or new diagnosis of an auto-immune disease: blood sampling for determination and neutralization of anti-IFN-I autoAbs, CBC, and biobanking (plasma and PBMCs) and collection of the hospitalization report in the case report form on a dedicated page.",[237,238,239,27],"Immunology","Allergy","Genetic Diseases",[241,242,243,244,186],"covid-19","auto-immunity","Type I interferon","kinetics","2025-09-02",{"date":247,"type":37},"2025-09-08",{"date":249,"type":37},"2025-04-09",{"date":251,"type":21},"2029-01",{"name":253,"class":254},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",9,{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":80,"phases":266,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100596656","omaha-system-based-health-application-on-improving-knowledge-attitude-and-behaviors-regarding-infectious-disease-prevention-in-the-community-100596656","NCT07048301","Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community","Developing an Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community","Inclusion criteria:\n\n* being aged between 18 and 64 years,\n* living in two container cities,\n* having a knowledge score of 'very low (1)' and 'low (2)' on the Omaha System Problem Rating Scale for Outcome for Communicable\u002F Infectious Problem Knowledge Parameter,\n* being literate,\n* owning a smartphone.\n\nExclusion criteria:\n\n* having impaired vision or hearing,\n* having a mental illness,\n* not owning a smartphone,\n* being pregnant or postpartum,\n* being participants in another scientific study,\n* refusing to participate.","64 Years",{"count":265,"type":21},112,[82],"Background: Infectious diseases remain significant public health concerns due to several factors such as climate and environmental changes and natural disasters. Mobile health applications (mHealth apps) can be an appropriate way for fostering community participation, disseminating knowledge, and promoting behavior change toward infectious disease prevention. This study aims to describe a protocol for a pilot randomized controlled study to evaluate the impact of the Omaha System-Based mHealth app (BUHOS) on improving knowledge, attitude, and behaviors (KAB) regarding infectious disease prevention in an earthquake-affected region of Türkiye.\n\nMethods: This study is a two-armed, parallel-group, randomized controlled trial design. A total of 112 eligible participants will be recruited from two separate container cities of an earthquake-affected region. These participants will be randomly allocated to either an intervention group or a control group. BUHOS will be designed based on the Omaha System, a widely recognized standardized taxonomy for the assessment, planning, and evaluation of healthcare services. BUHOS will be a two-week nursing intervention that includes monitoring KAB, employing Education, Guidance and Counseling (education videos), and Surveillance (reminder messages), and assessing the outcomes. Outcome variables will include the Problem Rating Scale for Outcomes, Community Communicable Diseases Knowledge Survey, Communicable Diseases Risk Awareness and Protection Scale and System Usability Scale. Outcome variables will be assessed on the 15th and 30th day after intervention.\n\nHypotheses:\n\nH1: Among the Omaha System Problems, the Communicable\u002F Infectious Condition Problem Knowledge score will be higher on the 15th and 30th days compared to the control group.\n\nH2: Infectious diseases risk awareness and prevention score will be higher on the 15th and 30th days compared to the control group.\n\nH3: Communicable\u002F Infectious Condition Status Behaviour Parameter score will be higher on the 15th and 30th days compared to the control group H4: The knowledge and behaviour of the communicable\u002F infectious status and the awareness and prevention of the risk of infectious diseases of the experimental group will be higher than before the intervention on the 15th and 30th days.",[27,269,270,271],"Attitude","Behavior","Knowledge",[273,274],"Omaha System","Mobile health app","2025-06-24",{"date":277,"type":37},"2025-07-02",{"date":279,"type":21},"2025-09",{"date":281,"type":21},"2026-06",{"name":283,"class":67},"Kocaeli University",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100571582","biobank-of-samples-from-patients-with-infectious-diseases-100571582","NCT06722131","Biobank of Samples From Patients With Infectious Diseases","Création d'Une biothèque de prélèvements de Patients présentant Une Pathologie Infectieuse","INFECTIOTEK","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Diagnosed with one of the following infectious diseases :\n\n  * Infection with HIV-1 or HIV-2, or person at risk of infection with HIV\n  * Viral hepatitis (HAV, HBV, HCV, HDV, HEV)\n  * Pulmonary infections: bacterial (notably Nocardia), viral (Influenza, RSV, SARS-CoV-2, Adenovirus), fungal (Aspergillus, Mucorales)\n  * Urinary tract infections\n  * Sexually transmitted infections (Neisseria gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum)\n  * Neuromeningeal infections: (Neisseria meningitidis, Streptococcus pneumoniae), viral (HSV, VZV), fungal (Cryptococcus).\n  * Infections affecting immunocompromised patients: herpes viruses (HSV, VZV, CMV, EBV), polyomavirus BK\n  * Emerging pathogen X (in the event of an epidemic)\n  * Signature of research consent form\n  * Health coverage with social security system or state medical aid\n\nExclusion Criteria:\n\n* Refusal to participate\n* Inability to give consent (cognitive impairment etc...)",{"count":293,"type":21},1000,"The aim of the INFECTIOTEK biobank will be to prospectively build a biobank of multiple biological samples from patients with infectious diseases in order to identify diagnostic and prognostic biomarkers, genetic susceptibility factors and immune response mechanisms in such diseases.\n\nThe population of the study will consist of patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care.\n\nThe diseases studied in this research project are bacterial infections (urinary tract infections, neurologic infections, sexually transmitted infections, pulmonary infections), viral infections (HIV, hepatitis, respiratory viruses, viruses affecting immunocompromised patients) and fungal infections (Aspergillus, Mucorales, Cryptococcus). These diseases are the domains of expertise and research of the clinical and biological teams at the Saint-Louis and Lariboisière hospitals.",[27],[297,298],"Biobank","Bacterial, viral and fungal diseases","2024-12-03",{"date":301,"type":37},"2024-12-09",{"date":303,"type":21},"2025-01-01",{"date":305,"type":21},"2031-01-01",{"name":307,"class":67},"Assistance Publique - Hôpitaux de Paris",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":80,"phases":317,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":119},"100413007","early-phase-1-lmp1-car-t-for-patients-with-lmp1-positive-infectious-diseases-and-hematological-malignancies-100413007","NCT04657965","LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies","Clinical Trial for the Safety and Efficacy of Sequential of LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies","Inclusion Criteria:\n\nOnly applicable to the inclusion criteria of CAEBV\n\n1. Subjects who are diagnosed with CAEBV according to the Okano revised standard proposed by the Japanese Ministry of Health, Labour and Welfare Research Group for the Prevention of Refractory Diseases;\n2. All CAEBV patients who have not achieved complete remission, including:\n\n   1. Active phase: EBV-DNA level in PBMC is higher than 1×10\\^2.5 copies\u002Fμg DNA, with symptoms and signs of active diseases such as fever, hepatomegaly, splenomegaly, abnormal liver function, decrease of blood three lines, lymphadenopathy, and progressive skin lesions with increased EBV titer in peripheral blood;\n   2. inactive phase: EBV-DNA level in PBMC is higher than 1×10\\^2.5 copies\u002Fμg DNA, without symptoms and signs of active diseases;\n3. The disease has not yet progressed to hematopoietic lymphohistiocytosis (HLH);\n\nOnly applicable to the inclusion criteria of LMP1-positive ENKTL:\n\n1. According to the 2016 WHO classification criteria for lymphocytic tumors: Subjects diagnosed by histopathology as extranodal NK\u002FT cell lymphoma, nasal type (ENKTL) with LMP1 positive in tumor tissue;\n2. R\u002FR ENKTL (meets one of the following prerequisites)\n\n   1. Without remission or with progression after receiving second-line or higher-line chemotherapy\u002Fchemotherapy + radiotherapy;\n   2. Primary drug resistance;\n   3. With recurrence after receiving autologous\u002Fallogeneic hematopoietic stem cell transplantation;\n3. According to 2014 Lugano standard, there should be at least one evaluable tumor lesion.\n\nOnly applicable to the inclusion criteria for LMP1-positive HL:\n\n1. According to the 2016 WHO classification criteria for lymphocytic tumors, subjects with Hodgkin lymphoma diagnosed by histopathology (HD) and LMP1 positive in tumor tissue;\n2. R\u002FR HD (meets one of the following prerequisites):\n\n   1. Without remission or with progression after receiving second-line or higher-line chemotherapy;\n   2. Primary resistance Drugs;\n   3. With recurrence after receiving autologous hematopoietic stem cell transplantation;\n3. According to the Lugano 2014 standard, there should be at least one evaluable tumor lesion;\n\nOnly applicable to the inclusion criteria for LMP1-positive PTLD:\n\n1. Only PTLD after hematopoietic stem cell transplantation;\n2. According to the 2016 WHO classification criteria for lymphocytic tumors, subjects with PTLD diagnosed by histopathology and LMP1 positive in tumor tissue;\n3. Excluding PTLD of early-stage\n4. R\u002FR PTLD (meets one of the following prerequisites):\n\n   1. Without remission or with progression after receiving rituximab-based standard treatment;\n   2. Primary drug resistance;\n5. According to the Lugano 2014 standard, there should be at least one evaluable tumor lesion\n\nExclusion Criteria:\n\nSubjects with any of the following exclusion criteria were not eligible for this trial:\n\n1. History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;\n2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n3. Pregnant (or lactating) women;\n4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);\n5. Active infection of hepatitis B virus or hepatitis C virus;\n6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;\n7. Previously treated with any CAR-T cell product or other genetically modified T cell therapies;\n8. Creatinine\\>2.5mg\u002Fdl, or ALT \u002F AST \\> 3 times of normal amounts, or bilirubin\\>2.0 mg\u002Fdl;\n9. Other uncontrolled diseases that were not suitable for this trial;\n10. Patients with HIV infection;\n11. Any situations that the investigator believes may increase the risk ofpatients or interfere with the results of study",{"count":316,"type":21},144,[318],"EARLY_PHASE1","A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies",[27,321],"Hematological Malignancies",[323,321,324,325],"Infectious diseases","CAR T-cell therapy","LMP1","2020-12-05",{"date":328,"type":37},"2020-12-08",{"date":330,"type":21},"2021-01-15",{"date":332,"type":21},"2027-01-15",{"name":334,"class":67},"Zhejiang University"]